From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024.
Researchers identified the enzyme CMPK2 as a possible target for therapies aiming to prevent metabolic dysfunction-associated ...
Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...
People with multiple sclerosis (MS) face a significantly higher risk of perinatal mental illness compared to those with other chronic conditions, according to a new study analyzing over 890,000 births ...
With every new year comes reflection and resolutions. But as we go to press well into January, it is worth a reminder that studies show nearly 90% ...
Researchers have developed a breakthrough method to detect inflammation in the body using positron emission tomography (PET) imaging. This innovative probe targets CD45, a marker abundantly expressed ...
Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...
Wearable devices like Apple Watches, Fitbits, and Oura Rings can monitor and predict inflammatory bowel disease activity.
Armed with positive data from a phase 2b trial, Teva and Sanofi ... become something of a hot topic in IBD, with other candidates also in mid- to late-stage clinical development.
Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...
According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...